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iTRAQ proteomic analysis of 
extracellular matrix remodeling in 
aortic valve disease
Tatiana Martin-Rojas1,*, Laura Mourino-Alvarez1,*, Sergio Alonso-Orgaz1, Esther Rosello-
Lleti2, Enrique Calvo3, Luis Fernando Lopez-Almodovar4, Miguel Rivera2, Luis R. Padial5, 
Juan Antonio Lopez3, Fernando de la Cuesta1 & Maria G. Barderas1
Degenerative aortic stenosis (AS) is the most common worldwide cause of valve replacement. The 
aortic valve is a thin, complex, layered connective tissue with compartmentalized extracellular matrix 
(ECM) produced by specialized cell types, which directs blood flow in one direction through the heart. 
There is evidence suggesting remodeling of such ECM during aortic stenosis development. Thus, a 
better characterization of the role of ECM proteins in this disease would increase our understanding 
of the underlying molecular mechanisms. Aortic valve samples were collected from 18 patients which 
underwent aortic valve replacement (50% males, mean age of 74 years) and 18 normal control valves 
were obtained from necropsies (40% males, mean age of 69 years). The proteome of the samples 
was analyzed by 2D-LC MS/MS iTRAQ methodology. The results showed an altered expression of 
13 ECM proteins of which 3 (biglycan, periostin, prolargin) were validated by Western blotting and/
or SRM analyses. These findings are substantiated by our previous results demonstrating differential 
ECM protein expression. The present study has demonstrated a differential ECM protein pattern in 
individuals with AS, therefore supporting previous evidence of a dynamic ECM remodeling in human 
aortic valves during AS development.
With a growing older population, cardiovascular diseases are becoming an increasing economic and 
social burden in Western societies. Cardiovascular calcification is a major characteristic of chronic 
inflammatory disorders such as chronic renal disease, atherosclerosis and calcific aortic valve disease, 
which are associated with significant morbidity and mortality1. Currently, degenerative aortic stenosis 
(AS) is the main cause of aortic valve replacement in developed countries. It is characterized by a nar-
rowing of the aortic valve opening which causes the obstruction of the blood flow from the left ventricle 
into the aorta2. With all this in mind, it is important to note that the ability of the valve to open and close 
repeatedly, as well as the maintenance of the phenotypes of valvular cells, is made possible by the tissue 
microstructure. This microstructure is influenced by the composition and orientation of the extracellular 
matrix (ECM). The ECM within the aortic valve is a dynamic environment rich in collagen, elastic fibers, 
proteoglycans and glycosaminoglycans, growth factors, proteases, signaling molecules and secreted pro-
teins3. The ECM provides an organized framework which enforces cell orientation and structural integ-
rity, allowing valve ability. Indeed, ECM is involved in valvular remodeling, which is typically described 
as a process composed of three main overlapping phases: inflammatory, proliferative and maturation4,5. 
Despite the growing evidence connecting ECM remodeling with AS pathogenesis, the underlying regu-
latory mechanisms for such remodeling and stratification are not well defined, even though they seem 
relevant to interpret aortic valve degeneration. In previous studies in our lab6, we conducted an in-depth 
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analysis of the secretome of aortic valves which pointed out an outstanding role of valvular remodeling 
in the pathophysiological mechanisms of AS. The functional classification of the differentially secreted 
proteins showed a significant number of ECM proteins. Since many ECM proteins are involved in AS, 
and taking into account its high prevalence and the long course of this disease, a better understanding of 
AS at the molecular level may be possible through a proteomic approach. This powerful technique might 
provide useful information to better understand the development of the disease. Besides, it may offer a 
new gate for the discovery of novel potential biomarkers shed to blood by the aortic valve, which may 
allow detecting patients at risk of developing degenerative AS, as a starting point.
In fact, previous studies of our group using two-dimensional difference in-gel electrophoresis 
(2D-DIGE) showed several ECM proteins altered with the progression of AS.6,7. According to our back-
ground, the aim of this work is to further clarify AS process and to ascertain whether ECM proteins 
might play a determinant role in AS. Here, we compared human AS valve tissue with that of healthy 
subjects using isobaric tags for relative and absolute quantitation (iTRAQ), a robust technique which 
presents more sensitivity and better accuracy of quantification than 2D-DIGE8 aiming to complement 
previous analyses with AS tissue using a deeper approach. Validation of 3 ECM proteins found altered 
was performed by orthogonal techniques (Western blotting and/or selected reaction monitoring (SRM)).
Results
Quantitative proteomics: iTRAQ labeling. To provide insight into the consequences of AS on 
protein expression, we compared the proteome of AS tissue with the one from healthy valves. Lysates 
from 4 control samples and 4 stenotic samples were iTRAQ labeled as shown in Fig. 1 of supplementary 
material (Figure SM1). Samples were pooled in four labeled peptide mixtures to allow the analysis of all 
of them in a limited number of LC-MS/MS runs avoiding labeling bias (for experimental design see sup-
plementary material). After the labeling procedure and liquid chromatography (LC) separation, derived 
peptides were identified and quantified by tandem mass spectrometry (MS/MS). The data generated by 
liquid chromatography coupled to mass spectrometry (LC-MS/MS) analysis were searched against the 
human RefSeq database using Proteome Discoverer software (Thermo Scientific).
iTRAQ ratios corresponding to 712 proteins between control and stenotic samples in four separate 
experiments were compared (Fig. 1).
For each experiment, we examined the original protein list generated by Protein Discoverer and 
filtered it according to the following criteria: a manual inspection of spectra was carried out wherever 
identification was supported among 90− 95% confidence values. Fold changes were calculated by com-
paring iTRAQ reporter ion intensities of peptides derived from AS and control valves (representative 
peptide MS/MS spectra and reporter ions of some differentially expressed proteins are shown in Fig. 2). 
Using 1.4-0.71 fold ratio as a cutoff to assign up or down-regulated proteins, we observed 56 differential 
proteins present in the four runs (mixtures) of the experiment, 34 up-regulated and 19 down-regulated 
in stenotic aortic valves, in addition to 3 proteins (haptoglobin, peptidyl-prolyl cis trans isomerase A, 
L-lactate dehydrogenase A chain isoform 1) which were increased or decreased depending on the iso-
form identified (Tables 1 and 2).
Annotation and functional enrichment. Functional analysis of the altered proteins was performed 
using DAVID v6.7. Molecular functions and biological processes were explored through the functional 
annotation tool to generate clusters of overrepresented Gene Ontology (GO) terms. This analysis showed 
13 significant clusters where the most significant cluster was formed by proteins from the extracellular 
region or matrix. This cluster is composed of 24 proteins of which 13 correspond to ECM proteins. 
Figure 1. Schematic representation of the proteins identified in the iTRAQ experiment. Within the 
712 identified proteins, 56 proteins (34 up-regulated and 19 down-regulated in stenotic aortic valves when 
compared to controls, in addition to 3 proteins which are increased or decreased depending on the isoform 
identified in stenotic valves when compared to controls) were detected in the four runs (mixtures) of the 
experiment carried out.
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Among most significantly enriched terms we observed oxidative stress, inflammatory response and pro-
teins related to muscle and cytoskeleton. ECM proteins together with oxidative stress proteins are pri-
marily involved in the biological AS process (Fig. 3A).
Protein-protein interaction. The 56 deregulated proteins determined in the iTRAQ experiment were 
introduced into the web-tool STRING v9.1 to generate protein-protein interaction networks (Fig.  3B). 
We selected exclusively the 13 ECM proteins which appeared altered in the iTRAQ experiment attending 
to the functional clustering and we analyzed them by web-tool STRING v9.1 too. (Fig. 3C).
After the clustering of ECM proteins, we found that the biggest group was composed by 5 proteins, all 
of which are tightly connected to each other (Fig. 3C, red cluster). Among these differentially expressed 
proteins were biglycan (BGN) with a control/patient ratio of 0.70, periostin (POSTN) with a ratio of 0.55 
and prolargin (PRELP) with a ratio of 0.59. These 3 proteins were identified in the four iTRAQ experi-
ments (mixtures) and were selected for the validation of the quantitative proteomic analysis.
Validation of the quantitative proteomic analysis. SRM. To validate the results obtained by 
proteomic analysis, the 3 proteins with altered expression profiles were monitored by SRM in an inde-
pendent group of samples (n = 10 controls, n = 10 AS patients).
For each protein, two peptides were quantified by SRM; in the case of periostin and prolargin, these 
peptides were found to differ significantly in their expression between groups (Fig. 4; Panel A = perios-
tin, peptide 1: p = 0.0022 and peptide 2: p = 0.0053 and panel B = prolargin, peptide1: p = 0.0086 and 
peptide 2: p = 0.0481) Unfortunately, we were not able to detect the peptides that correspond to biglycan 
by this technique.
Western blotting. We analyzed by WB two proteins: biglycan, not detected by SRM, and periostin with 
the goal in mind of confirming the reliability of both techniques. Overexpression of these proteins in AS 
valves compared to the control valves was confirmed (p = 0.021, p = 0.025, respectively) (Fig. 5).
Figure 2. (A) Example of one of the proteins identified after iTRAQ labeling and LC-MS/MS analysis. This 
protein was up-regulated in aortic stenosis (labeled with 115 and 117), with respect to control valves (labeled 
with 114 and 116). (1) MS/MS spectra after collision-induced dissociation (CID), (2) MS/MS fragmentation 
spectra after high-energy collision dissociation (HCD) for the analysis of low molecular masses, (3) detail 
of low molecular weight area after HCD fragmentation, showing the peaks that correspond to the reporter 
ions. (B) Quantification of reporter ion intensities for one of the proteins varied after iTRAQ label, biglycan. 
As can be observed, the ratio (114 + 116)/(115 + 117), in this case corresponding to controls/AS, is lower 
than the 0.71 cutoff, which means this protein is increased in AS.
www.nature.com/scientificreports/
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Protein Name
Accession 
Number Ratio Function
Histone H2A type 1-H gi 18105045 0.662 Complex assembly
Serotransferrin precursor gi 4557871 0.628 EC region/matrix; Inflammatory/immune response; Transport; Homeostasis
Protein Muted homolog isoform 1 gi 41152237 0.606 Homeostasis
Serum albumin preproprotein gi 4502027 0.603 EC region/matrix; Oxidative stress; Transport; Homeostasis; Vesicles
Calcineurin-binding protein cabin-1 
isoform a gi 6912458 0.600 Enzymatic activity
Superoxide dismutase [Mn], 
mitochondrial gi 67782309 0.561
Oxidative stress; Inflammatory/immune response; Transport; 
Homeostasis; Glucose metabolism; Complex assembly
Phosphoglycerate kinase 1 gi 4505763 0.550 Glucose metabolism
Alpha-1-antitrypsin gi 50363221 0.534 EC región/matrix; Oxidative stress; Infammatory/immune response; Enzymatic activity; Homeostasis; Vesicles
Serum amyloid P-component gi 4502133 0.478 EC region/matrix; Inflammatory/immune response; Binding; Complex assembly
Annexin A1 gi 4502101 0.660 Inflammatory/immune response; Cytoskeleton binding protein; Enzymatic activity; Homeostasis
Glutathione peroxidase 3 gi 6006001 0.577 EC region/matrix; Oxidative stress; Homeostasis; Complex assembly
Collagen alpha-1(VI) chain gi 87196339 0.663 EC región/matrix
Beta-galactoside-binding lectin L-14-I gi 4504981 0.659 EC region/matrix; Cytoskeleton organization; Homeostasis; Binding
Alpha-enolase gi 4503571 0.650 Muscle related protein; Transport; Glucose metabolism
L-lactate dehydrogenase A chain gi 5031857 0.650 Glucose metabolism
Triosephosphate isomerase isoform 1 gi 4507645 0.647 Oxidative stress; Homeostasis; Glucose metabolism
Moesin gi 4505257 0.644 Cytoskeleton protein binding
Peroxiredoxin-1 gi 4505591 0.644 Oxidative stress; Inflammation/immune response; Homeostasis; Glucose metabolism
Peptidyl-prolyl cis-trans isomerase A gi 10863927 0.629 Cytoskeleton protein binding
Similar to Ig gamma-1 chain C region gi 89037890 0.627 Homeostasis
Transforming growth factor-beta-
induced protein ig-h3 gi 4507467 0.624 EC región/matrix
Protein S100-A6 gi 7657532 0.597 Cell morphogenesis; Ion binding (NC)
Superoxide dismutase [Cu-Zn] gi 4507149 0.581
EC región/matrix; Oxidative stress; Inflammation/immune 
response; Muscle related protein; Cytoskeleton protein 
binding; Cytoskeleton organization; Homeostasis; Vesicles
Inter-alpha (globulin) inhibitor H1 gi 4504781 0.567 EC región/matrix; Enzymatic activity
Vimentin gi 62414289 0.586 Cytoskeleton protein binding
Prolargin gi 4506041 0.594 EC región/matrix; Binding
Tubulin beta chain gi 29788785 0.610 Cytoskeleton protein binding; Complex assembly
Alcohol dehydrogenase 1B gi 34577061 0.592 Oxidation/reduction (NC)
Annexin A2 gi 4757756 0.584 EC region/matrix; Cytoskeleton protein binding; Enzymatic activity; Vesicles
Endoplasmin precursor gi 4507677 0.532 Homeostasis; Vesicles
Periostin, osteoblast specific factor gi 5453834 0.550 EC region/matrix; Oxidative stress; Binding
Biglycan gi 4502403 0.701 EC región/matrix; Oxidative stress; Vesicles; Binding
Decorin isoform a preproprotein gi 4503271 0.610 EC región/matrix; Oxidative stress; Binding
Hemopexin gi 11321561 0.630 EC region/matrix; Oxidative stress; Transport; Homeostasis
Lumican gi 4505047 0.582 EC región/matrix
Haptoglobin gi 4826762 0.519 EC region/matrix; Inflammatory/immune response; Homeostasis
Orosomucoid 1 gi 9257232 0.515 EC region/matrix; Inflammatory/immune response
Table 1.  Proteins differentially expressed (upregulated in AS) and present in the four replicates from 
either of the two groups after 2D-LC iTRAQ analysis with a fold change <0.71 (RatioControl/AS).
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Discussion
Aortic stenosis is a progressive disease, often first manifesting as aortic valve sclerosis and later with 
valve dysfunction9. Valve dysfunction is characterized by a deregulation that depends upon the combined 
relationship between ECM, valve cells, and valve mechanics3. In fact, alterations in the normal arrange-
ment or composition of ECM significantly and detrimentally impact valve function producing a positive 
feedback loop. For this reason, there has been an increasing effort to characterize the ECM proteins in 
the context of AS. The study of proteins of interest by proteomic approaches is an excellent tool for the 
identification of tissue damage associated biomarkers, which may serve to specifically identify patients 
with poor prognosis10, as well as to understand the physiological/pathological processes leading to the 
development of AS. Following this idea we could remark that, until now, the sole comparative proteomic 
analyses of AS tissue valves have been recently performed by our group6,7, with the aim of understand-
ing the molecular mechanisms of this pathology by 2-D DIGE analysis of the aortic valve tissue and 
by LC-MS/MS to characterize valve secretome. Along the same line as these studies, we have identi-
fied a considerable amount of differential proteins involved in ECM processes in our study by iTRAQ, 
which strongly supports a deep involvement of ECM remodeling in AS pathogenesis. For this reason, 
and taking into account the complementarity of both techniques, we have supplemented our previous 
results with tissue secretome, with iTRAQ quantitative proteomics. Regarding this, we could broaden the 
knowledge about the disease by integrating the information related to secreted proteins with that of the 
molecular processes taking place inside the tissue.
With a cutoff of 1.4-fold upregulation and 0.71-fold downregulation, we could find 56 proteins to be 
significantly varied. Among these proteins, we found 13 proteins involved in ECM, with an outstanding 
cluster of 5 proteins formed by biglycan, periostin and prolargin, decorin and lumican. Of these pro-
teins, 3 of them were validated by orthogonal techniques (WB and/or SRM). Periostin was selected for 
validation due to the controversy that exists in the literature about the role of this protein in AS11,12. On 
the other hand, biglycan and prolargin have been related to the atherosclerotic lesion. Nowadays, the 
relationship between AS and atherosclerosis remains unclear13 and therefore a deeper study of these pro-
teins would favor to elucidate this link. Prolargin, lumican and decorin belong to the small leucine-rich 
proteoglycan (SLRPs) family and are closely related. Nevertheless, in contrast with lumican and decorin, 
the evidence about the involvement of prolargin in either atherosclerosis or AS is very limited. Besides, 
lumican was previously described and validated in AS patients by our group7.
If we focus on the molecular implications of these findings, we realize that periostin (POSTN) is a 
secreted protein expressed in cardiac fibroblasts, implicated in cardiac dysfunction14,15. It was first iden-
tified in bone, where it plays a key role regulating adhesion and differentiation of osteoblasts16,17. More 
recently, it has been suggested an involvement of POSTN in heart valve morphogenesis18–20 and cell 
migration12,21. Furthermore, Snider et al.20, demonstrated, that POSTN is an intriguing matrix effector 
protein that is required for normal ECM deposition within the heart, and suggests that POSTN may be 
required to enhance the fibrotic remodeling effects of TGFβ and stabilize microfibril networks within 
the cardiac skeleton, too. Our results showing over-expression of POSTN in stenotic valves point out a 
critical role of this protein in AS development, where it may contribute to small vessel formation as a 
result of its angiogenic activity22,23. It is important to note that this protein might enhance the penetration 
of microvessels into the subendothelial and fibrosa layers, which are the areas where the main anatomo-
pathological alterations take place in all types of valvular heart disease as reported by recent studies23,24. 
In particular, POSTN expression was detected in the subendothelial superficial layer of normal cardiac 
valves and it was greatly increased in the areas of neoangiogenesis24 in the degenerated valves of patients 
with valvular heart disease, such as those with stenotic or rheumatic valves. In addition, POSTN may 
contribute to valve calcification via its ability to provoke osteoblast differentiation since myofibroblasts 
differentiate to osteoblast-like cells in severe AS valves25.
Regarding biglycan (BGN), a small leucine-rich proteoglycan which organizes the fibril collagen 
assembly26, it has been defined as one of the major extracellular proteoglycans found in human ather-
osclerotic lesions27,28. Furthermore, it is considered an early initiator of AS lesion, contributing to wall 
thickening29. Previous reports have described a positive stimulation effect of pro-inflammatory factors 
in the ability of macrophage cells to synthesize BGN in atherosclerosis and in hypertension30. Thus, 
BGN levels are correlated with IL-6, TNF-α , fibrinogen and CRP plasma levels, suggesting that BGN 
might be involved in vascular inflammation31. It has been recently reported that macrophage cells are 
able to produce BGN upon stimulation by inflammatory factors26. Biglycan itself has been demonstrated 
to modulate the immune and inflammatory responses through the interaction with Toll-Like Receptor 
(TLRs) signaling cascade. Therefore, during inflammation, BGN may be released to the ECM or alterna-
tively could be induced in macrophage cells by cytokines, to signal through the interaction with TLRs. 
Subsequent expression of TNFα might result in increased recruitment of macrophages that release fur-
ther BGN, favoring the creation of a cycle that is capable to drive an inflammatory response in both an 
autocrine and a paracrine manner32. Recently, TLRs have been detected in stenotic valves33, in particular 
in valve interstitial cells (VICs)34, the main cellular component of the aortic valve. Moreover, studies 
indicate that TLRs may play a significant role in atherosclerosis35,36. Studies with animal models have 
demonstrated that BGN binds to murine TLR 2 and 4, whereby it induces the production of inflamma-
tory cytokines through the nuclear factor kappa B (NF-kB) pathway30. Taking into account the already 
postulated relationship between atherosclerosis and AS37 based on histological findings that point to 
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tissue mineralization, accumulation of lipids and inflammation38, the observed up-regulation of BGN in 
AS valves found in this work is in concordance with previous studies, and suggests this proteoglycan as 
an early initiator of the sclerotic lesion through an interaction with TLRs within the aortic valve.
In the same way, prolargin protein (PRELP) was found up-regulated in AS valve tissue39,40. This pro-
tein is present in all types of connective tissue. As the rest of the SLRPs, PRELP has a great affinity for 
the collagens I and II through its leucine-rich repeat domain41, joins fibroblasts through its N-terminal, 
and plays an important role in bone remodeling control42. Thus, PRELP could exert a similar effect to 
BGN in the development of AS calcification, together with other proteoglycans such as lumican and 
decorin43,44, which have been also found increased in AS in the iTRAQ analysis. The increase in AS of all 
the SLRPs detected in the present proteomic study may serve to fundament, once again, the relationship 
of this pathology with atherosclerosis36, given that lumican, decorin and prolargin are proteins involved 
in both pathologies which show similar expression trends43.
The main limitation of our study is the low number of samples included. Despite the fact that vali-
dation was performed in an independent cohort of subjects and by two different orthogonal techniques, 
it would be recommendable to increase the number of patients and controls in order to confirm the 
potential value of the hereby described protein indicators. Moreover, a prospective study will be required 
to determinate the clinical utility of these proteins as potential biomarkers which could allow distinguish-
ing patients at risk of developing degenerative AS. In conclusion, our results state the importance of the 
extracellular matrix remodeling in AS. The use of a comprehensive analysis of the aortic valve proteome 
Protein Name
Accession 
Number Ratio Function
Calponin-1 gi 21361120 3.035 Cytoskeleton protein binding; Cytoskeleton organization
Tropomyosin beta chain 
isoform 2 gi 47519616 2.408
Muscle related protein; Cytoskeleton protein binding; Cytoskeleton 
organization
Alpha-2-globin gi 4504345 2.323 Transport
Transgelin gi 48255905 2.219 Muscle related protein; Cytoskeleton binding protein
Myosin light polypeptide 6 gi 88999583 2.100 Muscle related protein; Cytoskeleton binding protein; Cytoskeleton organization
Tropomyosin alpha gi 63252902 1.868 Oxidative stress; Inflammation/immune response; Muscle related; Cytoskeleton protein binding; Cytoskeleton organization
Beta-1-globin gi 4504349 1.784 Oxidative stress; Transport
Haptoglobin gi 4826762 1.694 EC region/matrix; Inflammatory/immune response; Homeostasis
Delta-globin gi 4504351 1.581 Transport
Myosin-11 isoform SM2A gi 13124875 1.574 EC region/matrix; Muscle related protein; Cytoskeleton protein binding; Cytoskeleton organization; Vesicles; Complex assembly
Alpha-2-HS-glycoprotein gi 4502005 1.643 EC region/matrix; Inflammatory/immune response; Enzymatic activity
Actin, gamma-enteric smooth 
muscle isoform 1 gi 4501889 2.351
Oxidative stress; Muscle related protein; Cytoskeleton protein 
binding; Cytoskeleton organization
Apolipoprotein C-I gi 4502157 1.510 EC region/matrix; Enzymatic activity; Complex assembly
Filamin-1 gi 4503745 1.860 EC region/matrix; Muscle related protein; Cytoskeleton protein binding; Cytoskeleton organization; Complex assembly
Myosin-9 gi 12667788 1.830 Inflammation/immune response; Cytoskeleton protein binding; Cytoskeleton organization
Transgelin-2 gi 4507357 1.756 Muscle related protein
Milk fat globule-EGF factor 
8 protein gi 5174557 1.682 EC region/matrix; Enzymatic activity
Peptidyl-prolyl cis-trans 
isomerase A gi 10863927 1.639 Cytoskeleton protein binding
L-lactate dehydrogenase A 
chain isoform 1 gi 5031857 1.602 Glucose metabolism
Profilin-1 gi 4826898 1.589 Muscle related protein; Cytoskeleton protein binding; Cytoskeleton organization
Four and a half LIM domains 
protein 1 isoform 2 gi 21361122 1.521 Muscle related protein
Zinc finger protein 648 gi 58000461 1.529 Regulation of transcription (NC)
Table 2.  Proteins differentially expressed (downregulated in AS) and present in the four mixtures from 
either of the two groups after 2D-LC iTRAQ analysis with a fold change >1.4 (Ratio Control/AS).
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Figure 3. (A) Biological implications of the 56 differentially expressed proteins according to the functional 
annotation clustering. (B,C) Protein-protein interaction networks were studied using the STRING v9.1 web-
tool. Analyses of the 56 dysregulated proteins (B) and ECM proteins (C) are shown. Proteins with the same 
circle colours correspond to the same cluster, according to the classification performed using this tool.
Figure 4. Validation of differential proteins by SRM analysis. Graphical representation of the abundance 
(left panels) and representative extracted ion chromatograms (right panels) of the transitions observed 
for periostin (A) and prolargin (B). Significant increases (p < 0.05) in the expression of the measured 
proteotypic peptides of both proteins were observed in AS with respect to healthy valves. *p < 0.05; 
**p < 0.01. C: controls; AS: aortic stenosis; cps: counts per second.
www.nature.com/scientificreports/
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using 2D-LC MS/MS iTRAQ methodology has allowed the identification of a specific protein profile 
linked to the disease, highlighting the importance of the extracellular matrix proteins. Specifically, bigly-
can, periostin and prolargin have been pointed out as proteins of interest and have been validated using 
orthogonal techniques (WB and/or SRM). These results support the existence of a dynamic extracellular 
matrix remodeling in human aortic valves during AS development.
Material and Methods
Patient and control subjects’ selection. In this work, we employed the same samples used in our 
previous secretome study6. We obtained as many subjects as possible for this kind of proteomics analysis 
and we eliminated any potential bias inherent in their selection which meant a lot of effort over time, 
mainly in control samples. Heart valves with degenerative AS (n = 18) were obtained from patients of 
both sexes (50% male, 50% female), with an average age of 74 ± 4 years, who underwent aortic valve 
replacement due to severe degenerative AS. All patients (100%) had hypertension, whereas 55% suffered 
hyperlipemia and 66% diabetes mellitus. Coronary artery disease was present in 55% patients and sur-
gery was indicated according to current clinical practice guidelines. Patients with aortic regurgitation, 
mitral valve disease or any suspicion of rheumatic disease were not included in the study. Control valves 
were obtained from necropsies (n = 18). Before resecting the valve, a cardiac surgeon explored it care-
fully. Valves with calcifications or cusp restriction were excluded as control cases. If inserted saline in the 
aortic root remained in the closed valve, we ruled out significant regurgitation and we took these aortic 
valves as control cases. These subjects did not die from cardiovascular illnesses and had no history of 
coronary artery disease or diabetes mellitus (Table 3).
The study was conducted according to the recommendations of the Declaration of Helsinki and was 
approved by the ethics committee of Hospital Virgen de la Salud (Toledo, Spain). Signed informed con-
sent was obtained from all subjects or relatives in case of necropsies prior to their inclusion in the study.
Tissue Sample preparation. Aortic valves were processed according to Martin-Rojas et al.6 with 
minor modifications.
Briefly, AS valves were processed within a maximum of 2 hours after surgery having maintained the 
tissue at 4 °C in RPMI medium. The valves were washed 3 times in PBS to reduce blood contaminants. 
One aortic valve leaflet was then ground into powder in liquid N2 with a mortar and 0.2 g of this powder 
were resuspended in 400 μ l of protein extraction buffer (10 mM Tris [pH 7.5], 500 mM NaCl, 0.1% Triton 
x-100, 1% β -mercaptoethanol, 1 mM PMSF)45,46. The homogenate was centrifuged at 21,000 g (5840R 
Eppendorf) for 15 min at 4 °C to precipitate the membranes and tissue debris, and the supernatant (E1) 
containing most of the soluble proteins, was collected and stored at − 20 °C. The pellet was then solubi-
lized in 7M Urea, 2M Thiourea, 4% CHAPS47,48, and centrifuged again at 21,000 g. This second superna-
tant (E2) was collected and the cellular debris and lipids were eliminated with the pellet. Both protein 
extracts (E1 and E2) were pooled, and the protein concentration was determined by the Bradford-Lowry 
method (Bio-Rad protein assay)49.
iTRAQ labeling and SCX fractionation. iTRAQ labeling was carried out with an iTRAQ reagent 
4plex Protein Quantitation kit (AB Sciex) according to manufacturer’s protocol. The amount of 100 μ g of 
each aortic valve lysate was dissolved in 0.5 M triethylammonium bicarbonate (TEAB) (pH 8.5). Aortic 
valve proteins were reduced with 2 μ L of (tris(2-carboxyethyl) phosphine) (TCEP) at 60 °C for 1 h and 
alkylated with 1 μ L methyl methanethiosulfonate (MMTS) for 10 min at room temperature. Samples were 
digested using trypsin (porcine Promega) (1:40, w/w) for 16 h at 37 °C). Digested samples were further 
Figure 5. Western blot validation of the labeled proteins. (A) periostin (90 kDa) and (B) biglycan (40 kDa) 
levels increased in AS patients (P1 to P4) with respect the controls (C1 to C4). Corresponding p-values 
(Student’s t-test) for each protein analyzed are shown. *p < 0.05. RI: relative intensity.
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processed by labeling the derived peptides from control aortic valves with 114 and 116 iTRAQ labels, and 
from AS valves with 115 and 117, thus providing technical replicates within a single run (Table SM2).
The iTRAQ labeled peptides were pooled and fractionated by 2D-LC with strong cation exchange 
chromatography (SCX) followed by a C-18 reversed phase (RP) nano-column (100 μ m I.D. and 12 cm, 
Mediterranea sea, Teknokroma) and analyzed in a continuous acetonitrile gradient consisting of 0–43% 
B in 140 min, 50− 90% B in 1 min (B = 95% acetonitrile, 0.5% acetic acid). A flow rate of 300 nL/min 
was used to elute peptides from the RP nano-column to an emitter nanospray needle for real time ion-
ization and peptide fragmentation on an LTQ Orbitrap XL ETDTM mass spectrometer (Thermo Fisher). 
An enhanced FT-resolution spectrum (resolution = 60000) followed by the MS/MS spectra from most 
intense five parent ions were analyzed along the chromatographic run (180 min). Dynamic exclusion 
was set at 0.5 min. Expression changes were calculated using the reporter ion intensities (peaks areas) as 
control (114 + 116)/AS patients (115 + 117).
Protein identification and quantification were performed with the Protein Discoverer 1.0 software 
(Thermo Fisher) using MASCOT as the search engine. Two mixed cleavages were allowed, and an error 
of 15 ppm or 0.8 Da was set for full MS or MS/MS spectra searches, respectively. Decoy database search 
for FDR analysis was set at 0.05 by applying corresponding filters. Phosphorylation in Serine, Threonine, 
or Tyrosine was specified as variable modification due to the importance that this mechanism has in 
matrix remodeling50.
Bioinformatics analysis of identified proteins. For a functional examination of the identified pro-
teins, the list of the 56 significantly varied proteins was implemented on the on-line software David 
Bioinformatics Resources 6.7 (NIH)51 and Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING v9.1), for functional and protein interaction analyses, respectively.
Functional annotation clustering was performed in order to avoid redundancy of enriched categories 
and pathways (data not shown).
Selected Reaction Monitoring (SRM). Protein samples (10 AS patients and 10 controls) were 
reduced with 100 mM dithiothreitol (DTT, Sigma-Aldrich) in 50 mM ammonium bicarbonate (99% 
purity; Scharlau) for 30 min at 37 °C, and alkylated for 20 min at room temperature (RT) with 550 mM 
iodoacetamide (Sigma-Aldrich) in 50 mM ammonium bicarbonate. The proteins were then digested 
in 50 mM ammonium bicarbonate, 15% acetonitrile (LC-MS grade, Scharlau) with sequencing grade 
modified porcine trypsin at a final concentration of 1:50 (trypsin:protein). After overnight digestion 
at 37 °C, 2% formic acid (FA, 99.5% purity, Sigma-Aldrich) was added and the samples were cleaned 
with Pep-Clean spin columns (Pierce) according to the manufacturer’s instructions. Tryptic digests 
were dried in speed-vac and resuspended in 2% acetonitrile, 2% FA prior to MS analysis. The LC-MS/
MS system consisted of a TEMPO nano LC system (Applied Biosystems) combined with a nano LC 
autosampler coupled to a modified triple quadrupole (4000QTRAP LC/MS/MS, Applied Biosystems). 
Three replicate injections (2 μ g of protein in 4 μ L) were performed per sample in the mobile phase 
A (2% ACN/98% water, 0.1% FA) at a flow rate of 10 μ L/min for 5 min. Peptides were loaded onto a 
μ -Precolumn Cartridge (Acclaim Pep Map 100 C18, 5 μ m, 100 Å; 300 μ m i.d. X 5 mm, LC Packings) to 
preconcentrate and desalt samples. Reversed-phase liquid chromatography (RPLC) was performed on a 
C18 column (Onyx Monolithic C18, 150 × 0.1 mm I.D., Phenomenex) in a gradient of phase A and phase 
B (98% ACN/2% water, 0.1% FA). The peptides were eluted at a flow rate of 300 nL/min in a continuous 
acetonitrile gradient: 2–15% B for 2 min, 15–50% B for 38 min, 50 to 90% B for 2 min and 90% B for 
3 min. Both the TEMPO nano LC and 4000QTRAP system were controlled by Analyst Software v.1.4.2. 
The mass spectrometer was set to operate in positive ion mode with ion spray voltage of 2800 V and a 
nanoflow interface heater temperature of 150 °C. The source and curtain gas were set to 20 and 10 psi 
respectively, and nitrogen was applied as both curtain and collision gas.
Theoretical SRM transitions were designed using MRMpilot software v1.1 (ABSciex), with the follow-
ing settings: Enzyme = trypsin, missed cleavages = 0; modifications in peptide ≤ 3; charge states = + 1 
AS (n = 18) C (n = 18)
Age 74.4 ± 4 61 ± 16
Sex (%Male/Female) 50/50 83/17
% AHT 100 17
% Dyslipemia 55 —
% Diabetes 66 0
% Coronary disease 55 0
Table 3.  Clinical characteristics. The same samples that were used in our previous secretome study were 
employed in this work6. (AHT) arterial hypertension.
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from 300 to 600 Da, + 2 from 500 to 2000 Da, + 3 from 900 to 3000 Da, + 4 from 1600 to 4000 Da, 
+ 5 from 2400 to 10000 Da; studied modification = none; fixed modifications = carboxyamidomethyla-
tion; variable modifications = none; min. number of amino acids ≥ 5; max. number of amino acids ≤ 30; 
ignore multiple modification sites; 3 transitions per peptide (Table 4).
A pool containing a mixture of all the samples was digested as described previously and analyzed in 
the 4000QTrap using a MIDAS acquisition method that included the theoretical transitions. Transitions 
were selected when the three co-eluting peaks (corresponding to the three transitions of the same pep-
tide) had a signal-to-noise ratio over 5 and the MS/MS data matched the theoretical spectrum for that 
peptide. Collision energy was optimized to obtain the maximum transmission efficiency and sensitivity 
for each SRM transition. A total of 12 transitions (3 per peptide) were monitored during an individual 
sample analysis. They were acquired at unit resolution in both Q1 and Q3, with dwell times of 50 ms 
resulting in cycle times of 1.8 s. The IntelliQuan algorithm included in Analyst 1.4.2 software was used 
to calculate the peptide abundance on the basis of peak areas after integration.
Western blotting (WB). Protein samples obtained from 4 AS and 4 control valves were resolved by 
12% SDS-PAGE using a Miniprotean II electrophoresis unit (Bio-Rad) run at a constant current of 25 mA/
gel during 1 hour. After SDS-PAGE, the proteins were transferred to a nitrocellulose membrane under a 
constant voltage of 15 V for 20 minutes. To ensure that equal amounts of aortic valve tissue were loaded 
in every polyacrylamide gel well (1-DE Western blotting) Ponceau S staining was performed on the trans-
ferred membranes. The membranes were then blocked with 7.5% non-fat milk for 1 hour6. Next, they were 
incubated overnight at 4 °C with the primary antibody followed by a 1 hour RT incubation with the specific 
HRP-conjugated secondary antibody, both in PBS-T containing 5% of non-fat dry milk. Detection was per-
formed by enhanced chemiluminescence (ECL, GE Healthcare) following the manufacturers’ instructions.
The primary antibodies for Western blots included rabbit polyclonal antisera against periostin (cata-
log number: ab14041) and a monoclonal antibody against biglycan (catalog number: ab54855), all from 
Abcam (Abcam).
Statistical analysis. Western Blot bands were measured using a GS-800 Calibrated Densitometer 
(Bio-Rad) and the values obtained analyzed using the statistical software packages SPSS 13.0 and 
GraphPad InStat (GraphPad software). A Kolmogorov-Smirnov test was applied to evaluate normal dis-
tribution of the population analyzed. When normal distribution was demonstrated, a Levene test for 
homogeneity of variance was performed and the Student t-test was used to compare band intensities 
and SRM peak areas, selecting adequate p-value in view of homogeneity results. For populations with 
no normal distribution, the non-parametric Mann-Whitney U test was used. For all tests, statistical sig-
nificance was accepted when p < 0.05. All LC-MS/MS identifications were performed by Decoy database 
search for FDR analysis set at 0.05 by applying corresponding filters (Mascot Significance Threshold, and 
Score versus Charge state).
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